Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.4K
Overview
44.4K
Cancer Vaccines01:30

Cancer Vaccines

360
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
360
Clinical Trials01:16

Clinical Trials

6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K
International Nursing Organizations II01:28

International Nursing Organizations II

1.0K
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
1.0K
Torts III01:26

Torts III

665
Types of Quasi-intentional Torts in Healthcare
Quasi-intentional torts in healthcare involve acts where intent is not directed to harm an individual but results in harm due to careless or reckless speech.
665
Tumor Immunotherapy01:27

Tumor Immunotherapy

522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overcoming the energy-dependent barrier to aminoglycoside uptake: multimodal strategies to sensitize <i>Staphylococcus aureus</i> persisters.

Microbiology and molecular biology reviews : MMBR·2026
Same author

Burden of COVID-19 in Korean Children: A Retrospective Observational Study Using Real-world Data.

The Pediatric infectious disease journal·2026
Same author

Efficacy and safety of Doxycycline versus Macrolides for <i>Mycoplasma pneumoniae</i> INfectiOn in Children (DOMINO): a protocol for a multicentre, randomised, open-label, superiority trial.

BMJ open·2026
Same author

BCG vaccination in Korea, Japan, and Taiwan: Current status and future perspectives.

Human vaccines & immunotherapeutics·2026
Same author

Pediatric COVID-19 in Korea: Lessons and Strategies for Future Disease-X Preparedness.

Journal of Korean medical science·2026
Same author

Determinants and Patterns of Antibiotic Use in Children Under Five in Cambodia: Analysis of Demographic and Health Survey Data 2010-2022.

Infection & chemotherapy·2026

Related Experiment Video

Updated: Jun 28, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K

COVID-19 Vaccine Injury Compensation Program: Lessons Learned From a Review of 10 Implementing Countries.

Cho Ryok Kang1, Young June Choe2, Seok-Jun Yoon3

  • 1Allergy Immunology Center, Korea University, Seoul, Korea.

Journal of Korean Medical Science
|April 10, 2024
PubMed
Summary
This summary is machine-generated.

South Korea

Keywords:
COVID-19CompensationVaccinationVaccines

More Related Videos

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

5.9K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.8K

Related Experiment Videos

Last Updated: Jun 28, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.7K
High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

5.9K
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

42.8K

Area of Science:

  • Public Health
  • Immunization Policy
  • Health Law

Background:

  • The National Vaccine Injury Compensation Program (NVICP) in South Korea, established in 1995, provides a safety net for vaccine-related injuries.
  • The COVID-19 pandemic highlighted limitations in the Korean NVICP, including strict causality criteria, opaque decision-making, and inadequate compensation amounts.
  • Effective vaccine injury compensation is vital for public trust and adherence to national vaccination policies during health crises.

Purpose of the Study:

  • To analyze the limitations of South Korea's National Vaccine Injury Compensation Program (NVICP) during the COVID-19 pandemic.
  • To review vaccine injury compensation programs in 10 major countries to identify best practices for improving the Korean system.
  • To propose actionable recommendations for enhancing national accountability and efficiency in vaccine injury compensation.

Main Methods:

  • Comparative analysis of vaccine injury compensation programs in 10 major countries.
  • Identification of specific program features contributing to more effective compensation.
  • Review of legal and administrative frameworks governing vaccine injury claims.

Main Results:

  • Several countries (Germany, Japan, Taiwan) utilize more relaxed causality criteria for vaccine injury claims.
  • Mandatory preliminary compensation (Thailand) and practical compensation amounts (Germany, France, Japan) improve claimant support.
  • Transparent processes, including record sharing (France, UK), enhance claimant trust and system efficiency.
  • Dedicated vaccine injury compensation agencies (France, UK, Australia) streamline the process.

Conclusions:

  • South Korea's NVICP requires significant reform to address pandemic-related challenges.
  • Adopting international best practices, such as relaxed causality criteria and transparent processes, is essential.
  • Establishing a dedicated agency and ensuring practical compensation are crucial for an effective national vaccine injury compensation system.